Pharmaceutically active agents that impede amyloid formation in vivo
AssigneeDMS Pharmaceutical Inc.
InventorPaul Averback
Life of this patent
Estimating the term…
Abstract
Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at in-tissue concentrations of 10−5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis.
Claims7
A composition comprising (a) an amyloid fibril inhibitory effective amount of a compound that inhibits formation of amyloid fibrils when administered, at an in-tissue concentration of about 10−5 or less, to a test animal that has received an intracerebral injection of DMS wherein said compound is selected from the group consisting of pyrimethamin, cromolyn sodium, erythyromycin, purpurogallin, tartrazine, sulfanilamide, benzopurpurine, benzopurpurine 4B, 29H, 31H-phthalocyanine, 5-methyl-2-thiouridine and 1,2-benzylsoxazole and (b) a pharmaceutically acceptable carrier, wherein said composition is capable of crossing the blood-brain barrier.
Dependencies are inferred from the claim text.